Eglin Pharma to Unveil Global First-in-Class EG-501 Phase II Data for NPSLE-Related Cognitive Impairment at the 10th China Medical Innovation and Investment Congress

On October 26-27, the 10th Pharmaceutical Innovation and Investment Conference will be held in Nanjing. This conference is co-hosted by the China Pharmaceutical Innovation and Research Development Association and the Hong Kong Stock Exchange. As a benchmark platform for the transformation of innovative drug research results in China, over the past nine years, the conference’s “Global First Release of Clinical Data Session” has showcased 77 high-quality ongoing projects to attendees, most of which are Class 1 innovative drugs that fill clinical gaps. At that time, Dr. Changqing Li, Co-founder and Chief Medical Officer of Evergreen Therapeutics, will...First Global Release of Phase II Clinical Trial Data for "First in Disease" Drug EG-501, injecting cutting-edge vitality from AI-driven drug discovery into this "decade-long commitment."

EG-501 is a small molecule oral tablet for the treatment of cognitive impairment in neuropsychiatric systemic lupus erythematosus (NPSLE). Cognitive impairment, commonly known as "brain fog," presents as a series of symptoms including lack of focus, memory decline, and slow thinking. As one of the common complications of lupus, cognitive impairment severely affects patients' quality of life and social functioning, yet this area...No approved drugs are currently available., there is a huge unmet clinical need. EG-501 has undergone a multi-center, randomized, placebo-controlled, double-blind Phase II trial at three renowned academic centers including Vanderbilt University Medical Center in the United States. The trial aims to evaluate its efficacy and safety in patients with NPSLE cognitive impairment and has achieved breakthrough positive results.

As one of the core pipelines deeply involved by Evergreen Therapeutics' self-developed AI platformThe EG-501 project started with AI modeling and innovatively applied machine learning algorithms such as PheWAS analysis, LASSO, and Random Forest to deeply explore the associations between targets and diseases. The project introduced large-scale high-quality data from top-tier academic medical centers in the United States, including whole-genome data covering more than 12,000 exome sequencing results, 250,000 genetic coding variants, and target-related SNPs. The de-identified medical case database contains information on 35,000 subjects, covering approximately 1,600 different disease phenotypes. Based on this, the platform used precise feature selection to identify 12 disease phenotypes related to the target from massive amounts of data, further combining market demand with commercial value assessment.Finally, it was determined to use NPSLE cognitive impairment as the indication for Phase II clinical trials, establishing a complete technical closed-loop from data to clinical direction.In the design of clinical trial protocols, the application of AI technology has significantly improved the efficiency of selecting enrolled patients. By precisely targeting the desired patient population, it achieves statistical significance with fewer enrolled patients, effectively reducing trial costs.

Dr. Tao Du, Founder and Chairman of Evergreen Therapeutics, stated:"The Phase II data of EG-501 validated its efficacy in cognitive function and demonstrated good safety. We believe it has the potential to become the world's first approved drug for the effective treatment of NPSLE-related cognitive impairment. At the same time, this achievement fully confirms the practical value of Evergreen Therapeutics' self-developed AI platform in drug development, which can support similar research efforts such as..."Treatment of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and Sjögren's syndrome, as well as neurodegenerative diseases like Parkinson's disease with cognitive impairment and sepsis"Providing replicable and scalable potential pathways."